Peter Norman
Peter Norman
Atrasentan is a selective endothelin ET(A) receptor antagonist under development by Abbott for the potential treatment of cancer, particularly prostate cancer, for which it is in phase III trials [413197]. In July 2002, phase II trials for ...
J Ruth Wu-Wong
J Ruth Wu-Wong
Endothelins (ETs) are 21-amino acid peptides involved in many different pathological conditions. ETs, mediated by the ET(A) receptor, are mitogenic for many types of cancer cells. ETs seem to both promote and inhibit apoptosis, dependent on...
Iftekhar Mahmood
Iftekhar Mahmood
Somerset is developing a selegiline transdermal system (STS) for potential use in the treatment of depression. It has also been developed for Alzheimer's disease (AD), Parkinson's disease and attention-deficit hyperactivity disorder (ADHD) ...
Aimee L McRae
Aimee L McRae
Lundbeck and Forest have developed and launched escitalopram, the therapeutically active (S)-enantiomer of citalopram, as an improved follow-up compound for the potential treatment of depression. In December 2001, Lundbeck received Swedish ...
MethyPatch Noven [0.03%]
甲氨蝶呤补片(Noven)
Natasha Sane,James J McGough
Natasha Sane
Noven Pharmaceuticals is developing a transdermal patch formulation of methylphenidate for the treatment of attention deficit hyperactivity disorder (ADHD) [325808]. Phase III trials were completed in February 2002 [438893]; at this time, t...
Duloxetine Eli Lilly [0.03%]
灵北的度洛西汀
Sami Anttila,Esa Leinonen
Sami Anttila
Duloxetine is a serotonin (5-HT) and norepinephrine (NE) uptake inhibitor in pre-registration for depression. In vivo studies demonstrate that duloxetine inhibits 5-HT and NE transporters and this may induce an antidepressant effect [159168...
David J Posey,Christopher J McDougle
David J Posey
Autistic disorder (autism) is a neuropsychiatric syndrome characterized by marked deficits in reciprocal social relatedness, communication impairment and a narrow range of interests and/or repetitive behaviors. Autism is frequently associat...
Julie B Schweitzer,Henry H Holcomb
Julie B Schweitzer
There has been substantial development of pharmacological treatments for attention-deficit hyperactivity disorder (ADHD) recently. The greatest change is the approval of new delivery systems for methylphenidate (MPH) and amphetamine (AMP) t...
Antonio Preti
Antonio Preti
Serendipity and hypothesis-driven research both contributed to the discovery and characterization of two recently identified neuropeptides thought to be involved in the control of appetite and arousal. These two peptides, named hypocretin-1...
ART-123 Asahi Kasei [0.03%]
亚塞希凯莎公司艺术类作品编号123
Sascha Khorchidi,Ruediger Bantleon,Rainer Kehlbach et al.
Sascha Khorchidi et al.
Asahi Kasei is developing a recombinant thrombomodulin (ART-123), a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disse...